Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2013

Open Access 01-12-2013 | Debate

How confidence intervals become confusion intervals

Authors: James McCormack, Ben Vandermeer, G Michael Allan

Published in: BMC Medical Research Methodology | Issue 1/2013

Login to get access

Abstract

Background

Controversies are common in medicine. Some arise when the conclusions of research publications directly contradict each other, creating uncertainty for frontline clinicians.

Discussion

In this paper, we review how researchers can look at very similar data yet have completely different conclusions based purely on an over-reliance of statistical significance and an unclear understanding of confidence intervals. The dogmatic adherence to statistical significant thresholds can lead authors to write dichotomized absolute conclusions while ignoring the broader interpretations of very consistent findings. We describe three examples of controversy around the potential benefit of a medication, a comparison between new medications, and a medication with a potential harm. The examples include the highest levels of evidence, both meta-analyses and randomized controlled trials. We will show how in each case the confidence intervals and point estimates were very similar. The only identifiable differences to account for the contrasting conclusions arise from the serendipitous finding of confidence intervals that either marginally cross or just fail to cross the line of statistical significance.

Summary

These opposing conclusions are false disagreements that create unnecessary clinical uncertainty. We provide helpful recommendations in approaching conflicting conclusions when they are associated with remarkably similar results.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cowles M, Davis C: On the origins of the.05 level of statistical significance. Am Psychol. 1982, 37: 553-558.CrossRef Cowles M, Davis C: On the origins of the.05 level of statistical significance. Am Psychol. 1982, 37: 553-558.CrossRef
2.
go back to reference Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC: Effect of different antilipidemic agents and diets on mortality: A Systematic Review. Arch Intern Med. 2005, 165: 725-730. 10.1001/archinte.165.7.725.CrossRefPubMed Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC: Effect of different antilipidemic agents and diets on mortality: A Systematic Review. Arch Intern Med. 2005, 165: 725-730. 10.1001/archinte.165.7.725.CrossRefPubMed
3.
go back to reference Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK: Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006, 166: 2307-2313. 10.1001/archinte.166.21.2307.CrossRefPubMed Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK: Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006, 166: 2307-2313. 10.1001/archinte.166.21.2307.CrossRefPubMed
4.
go back to reference Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D: Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008, 52: 1769-1781. 10.1016/j.jacc.2008.08.039.CrossRefPubMed Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D: Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008, 52: 1769-1781. 10.1016/j.jacc.2008.08.039.CrossRefPubMed
5.
go back to reference Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, et al: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009, 338: b2376-10.1136/bmj.b2376.CrossRefPubMedPubMedCentral Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RGJ, et al: The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009, 338: b2376-10.1136/bmj.b2376.CrossRefPubMedPubMedCentral
6.
go back to reference Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I, et al: Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010, 170: 1024-1031. 10.1001/archinternmed.2010.182.CrossRefPubMed Ray KK, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I, et al: Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med. 2010, 170: 1024-1031. 10.1001/archinternmed.2010.182.CrossRefPubMed
7.
go back to reference Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361: 1139-1151. 10.1056/NEJMoa0905561.CrossRefPubMed Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361: 1139-1151. 10.1056/NEJMoa0905561.CrossRefPubMed
8.
go back to reference Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365: 981-992. 10.1056/NEJMoa1107039.CrossRefPubMed Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365: 981-992. 10.1056/NEJMoa1107039.CrossRefPubMed
10.
go back to reference Singh S, Loke YK, Spangler JG, Furberg CD: Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011, 183: 1359-1366. 10.1503/cmaj.110218.CrossRefPubMedPubMedCentral Singh S, Loke YK, Spangler JG, Furberg CD: Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ. 2011, 183: 1359-1366. 10.1503/cmaj.110218.CrossRefPubMedPubMedCentral
11.
go back to reference Prochaska JJ, Hilton JF: Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012, 344: e2856-10.1136/bmj.e2856.CrossRefPubMedPubMedCentral Prochaska JJ, Hilton JF: Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012, 344: e2856-10.1136/bmj.e2856.CrossRefPubMedPubMedCentral
12.
go back to reference Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK: Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012, 172: 209-216. 10.1001/archinternmed.2011.628.CrossRefPubMed Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK: Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012, 172: 209-216. 10.1001/archinternmed.2011.628.CrossRefPubMed
13.
go back to reference Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J: Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011, 124: 621-629. 10.1016/j.amjmed.2011.01.018.CrossRefPubMed Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J: Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med. 2011, 124: 621-629. 10.1016/j.amjmed.2011.01.018.CrossRefPubMed
15.
16.
go back to reference Gardner MJ, Altman DG: Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed). 1986, 292: 746-750. 10.1136/bmj.292.6522.746.CrossRef Gardner MJ, Altman DG: Confidence intervals rather than P values: estimation rather than hypothesis testing. Br Med J (Clin Res Ed). 1986, 292: 746-750. 10.1136/bmj.292.6522.746.CrossRef
18.
go back to reference Bulpitt CJ: Confidence intervals. Lancet. 1987, 329 (8531): 494-497. 10.1016/S0140-6736(87)92100-3.CrossRef Bulpitt CJ: Confidence intervals. Lancet. 1987, 329 (8531): 494-497. 10.1016/S0140-6736(87)92100-3.CrossRef
19.
go back to reference Cooper RJ, Wears RL, Schriger DL: Reporting research results: recommendations for improving communication. Ann Emerg Med. 2003, 41: 561-564. 10.1067/mem.2003.135.CrossRefPubMed Cooper RJ, Wears RL, Schriger DL: Reporting research results: recommendations for improving communication. Ann Emerg Med. 2003, 41: 561-564. 10.1067/mem.2003.135.CrossRefPubMed
20.
go back to reference Cummings P, Koepsell TD: P values vs estimates of association with confidence intervals. Arch Pediatr Adolesc Med. 2010, 164: 193-196. 10.1001/archpediatrics.2009.266.PubMed Cummings P, Koepsell TD: P values vs estimates of association with confidence intervals. Arch Pediatr Adolesc Med. 2010, 164: 193-196. 10.1001/archpediatrics.2009.266.PubMed
Metadata
Title
How confidence intervals become confusion intervals
Authors
James McCormack
Ben Vandermeer
G Michael Allan
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2013
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/1471-2288-13-134

Other articles of this Issue 1/2013

BMC Medical Research Methodology 1/2013 Go to the issue